TGN1412
Also known as CD28-SuperMAB, TAB08
Theralizumab (also known as TGN1412, CD28-SuperMAB, and TAB08) is an immunomodulatory drug developed by immunologist of the University of Würzburg. It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by Parexel in London in March 2006. The developing company, TeGenero Immuno Therapeutics (), a spin-off of the University of Würzburg around immunologist Thomas Hünig, co-founder and chief scientific officer (CSO) Thomas Hanke and chief executive officer (CEO) Benedikte Hatz went bankrupt later that year. The c
Article · Svenska
TGN1412, även känt som CD28-SuperMAB®, är arbetsnamnet för ett immunsystemmodulerande läkemedel, ursprungligen utvecklad av TeGenero som en behandling av kronisk lymfatisk leukemi i B-celler samt ledgångsreumatism.
Abstract from DBpedia / Wikipedia · CC BY-SA
Gallery (2)
Connections
Categories
2006 in LondonAbandoned drugsChemical pages without DrugBank identifierChemicals that do not have a ChemSpider ID assignedClinical trial disastersDrugboxes which contain changes to watched fieldsDrugs not assigned an ATC codeDrugs that are a monoclonal antibodyDrugs with non-standard legal statusExperimental monoclonal antibodiesMonoclonal antibodies